Company Profile
Teva Pharmaceutical Industries Stock Price, News & Analysis
- Ticker:
- TEVA
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- Israel and listed in the U
Stock performance
34.81 USD (+0.26%)
Close
Last updated: August 6, 2026
38.5B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, TEVA closed up 0.26% at $34.81. No new same-company headline was identified in the current news window.
Company overview
Global Generics and Innovative Medicines Company
Teva Pharmaceutical Industries is a global pharmaceutical company combining a large generics base with a growing innovative medicines portfolio. Its current strategy, Pivot to Growth, is shifting the company toward higher-value innovative brands, biosimilars, and late-stage pipeline assets while modernizing operations.
Innovative Brand Growth
Teva's key innovative brands are AUSTEDO, AJOVY, and UZEDY. Together they generated more than $1 billion in second-quarter 2026 revenue and grew 43% year over year in local currency. This portfolio is transforming Teva's revenue mix and supports the company's raised 2026 outlook for all three brands.
Generics and Biosimilars Powerhouse
Generics revenue declined in the quarter, largely due to lower U.S. lenalidomide revenue as competition increased. At the same time, Teva is building biosimilars as a growth area, including the European launch of AHZANTIVE and a collaboration with Polpharma Biologics for a proposed Ocrevus biosimilar.
Late-Stage Neuroscience and Immunology Pipeline
Teva is expanding its innovative pipeline through assets such as ecopipam for Tourette syndrome, olanzapine LAI for schizophrenia, TEV-'408 for vitiligo, and duvakitug with Sanofi for inflammatory bowel disease and additional immune-mediated indications. This gives the company a more diversified growth profile beyond mature generics.
Future catalysts
Potential U.S. launch of olanzapine LAI in the fourth quarter of 2026, subject to approval.
FDA review of ecopipam after NDA submission in June 2026.
Phase 2 initiation for TEV-'408 in vitiligo expected in the fourth quarter of 2026.
Additional duvakitug studies in hidradenitis suppurativa and fibrostenotic Crohn's disease.
Recent news
- 01
Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
Source: Teva Pharmaceutical Industries
- 02
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Source: Teva Pharmaceutical Industries
- 03
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
Source: Teva Pharmaceutical Industries
- 04
Teva Releases Q2 2026 Aide Memoire
Source: Teva Pharmaceutical Industries
- 05
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
Source: Teva Pharmaceutical Industries
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Teva Pharmaceutical Industries (TEVA)?
Teva Pharmaceutical Industries (TEVA) most recently closed at 34.81 USD, a +0.26% move versus the previous session.
What is the market cap of Teva Pharmaceutical Industries (TEVA)?
Teva Pharmaceutical Industries currently has a market capitalization of 38.5B USD on BioPharmSignal.
What does Teva Pharmaceutical Industries do?
Global Generics and Innovative Medicines Company Teva Pharmaceutical Industries is a global pharmaceutical company combining a large generics base with a growing innovative medicines portfolio. Its current strategy, Pivot to Growth, is shifting the company toward higher-value innovative brands, biosimilars, and late-stage pipeline assets while modernizing...
On which exchange is TEVA stock listed?
Teva Pharmaceutical Industries (TEVA) is associated with NYSE, Israel and listed in the U, Biopharma.
What is Global?
Global Generics and Innovative Medicines Company Teva Pharmaceutical Industries is a global pharmaceutical company combining a large generics base with a growing innovative medicines portfolio.
Which conditions is Teva Pharmaceutical Industries targeting with Global?
Teva Pharmaceutical Industries is associated with immunology, neuroscience based on its company overview and current catalyst commentary.
How does Teva Pharmaceutical Industries describe recent progress with Global?
Potential U.S. launch of olanzapine LAI in the fourth quarter of 2026, subject to approval. FDA review of ecopipam after NDA submission in June 2026. Phase 2 initiation for TEV-'408 in vitiligo expected in the fourth quarter of 2026. Additional duvakitug studies in hidradenitis suppurativa and fibrostenotic Crohn's disease.
What is Generics?
Global Generics and Innovative Medicines Company Teva Pharmaceutical Industries is a global pharmaceutical company combining a large generics base with a growing innovative medicines portfolio.